Literature DB >> 22626557

Differentiating benign from malignant thyroid nodules using micro ribonucleic acid amplification in residual cells obtained by fine needle aspiration biopsy.

Haggi Mazeh1, Yair Levy, Ido Mizrahi, Liat Appelbaum, Nadia Ilyayev, David Halle, Herbert R Freund, Aviram Nissan.   

Abstract

BACKGROUND: Fine needle aspiration biopsy (FNAB) is the most commonly used diagnostic tool to differentiate benign from malignant thyroid nodules. Nevertheless, some FNAB cytology results are not definite. In such cases diagnostic thyroid lobectomy is performed with malignancy rate on final histopathology ranging at 15%-75%. The aim of this study was to improve on the accuracy of FNAB-based cytology by amplification of microRNAs (micro ribonucleic acids [miRs]) from the residual cells left in the FNAB needle after submission for cytology.
METHODS: Residual cells were collected from the needle cup after FNAB cytology of 77 consecutive patients with thyroid nodules. miR-enriched RNA was extracted for all patients with cytology showing either follicular lesion or suspicion for malignancy (n=11). The expression of miR-21, -31, -146b, -187, -221, and -222 was determined using real-time polymerase chain reaction. Results were compared with final surgical histopathology.
RESULTS: RNA was successfully extracted from all FNAB specimens. Five patients had FNAB cytology suspicious for malignancy. The miR panel was positive in all five (100%). Six patients had follicular lesions on FNAB. The miR panel was positive in three of four patients (75%) with confirmed malignancy and was negative in two of two (0%) patients with benign pathology results. This corresponded to a specificity of 100%, sensitivity of 88%, and accuracy of 90%.
CONCLUSIONS: RNA extraction from FNAB residual cells is feasible, and a miR panel amplified from the extracted RNA seems like a promising diagnostic tool in this limited number of patients.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22626557     DOI: 10.1016/j.jss.2012.04.051

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  11 in total

Review 1.  MicroRNAs in the thyroid.

Authors:  Myriem Boufraqech; Joanna Klubo-Gwiezdzinska; Electron Kebebew
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2016-11-01       Impact factor: 4.690

2.  Diagnostic value of microRNAs in discriminating malignant thyroid nodules from benign ones on fine-needle aspiration samples.

Authors:  Yang Zhang; Qi Zhong; Xiaohong Chen; Jugao Fang; Zhigang Huang
Journal:  Tumour Biol       Date:  2014-06-19

Review 3.  MicroRNA as a diagnostic tool in fine-needle aspiration biopsy of thyroid nodules.

Authors:  Haggi Mazeh
Journal:  Oncologist       Date:  2012-06-15

4.  The clinical utility of microRNA-21 as novel biomarker for diagnosing human cancers.

Authors:  Lijun Shen; Zhihong Wan; Yuming Ma; Libing Wu; Fangfang Liu; Hong Zang; Shaojie Xin
Journal:  Tumour Biol       Date:  2014-11-28

Review 5.  Molecular Characterization of Thyroid Follicular Lesions in the Era of "Next-Generation" Techniques.

Authors:  Esther Diana Rossi; Pietro Locantore; Carmine Bruno; Marco Dell'Aquila; Pietro Tralongo; Mariangela Curatolo; Luca Revelli; Marco Raffaelli; Luigi Maria Larocca; Liron Pantanowitz; Alfredo Pontecorvi
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-12       Impact factor: 6.055

Review 6.  MicroRNAs (miRNAs) as biomarker(s) for prognosis and diagnosis of gastrointestinal (GI) cancers.

Authors:  Muzafar A Macha; Parthasarathy Seshacharyulu; Shiv Ram Krishn; Priya Pai; Satyanarayana Rachagani; Maneesh Jain; Surinder K Batra
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

7.  The evaluation of miRNAs on thyroid FNAC: the promising role of miR-375 in follicular neoplasms.

Authors:  Esther Diana Rossi; Tommaso Bizzarro; Maurizio Martini; Sara Capodimonti; Diletta Sarti; Tonia Cenci; Mirna Bilotta; Guido Fadda; Luigi Maria Larocca
Journal:  Endocrine       Date:  2016-01-27       Impact factor: 3.633

Review 8.  Molecular Signature of Indeterminate Thyroid Lesions: Current Methods to Improve Fine Needle Aspiration Cytology (FNAC) Diagnosis.

Authors:  Silvia Cantara; Carlotta Marzocchi; Tania Pilli; Sandro Cardinale; Raffaella Forleo; Maria Grazia Castagna; Furio Pacini
Journal:  Int J Mol Sci       Date:  2017-04-06       Impact factor: 5.923

Review 9.  The Role of Molecular Testing for the Indeterminate Thyroid FNA.

Authors:  Esther Diana Rossi; Liron Pantanowitz; William C Faquin
Journal:  Genes (Basel)       Date:  2019-09-23       Impact factor: 4.096

10.  miRNA-106a directly targeting RARB associates with the expression of Na(+)/I(-) symporter in thyroid cancer by regulating MAPK signaling pathway.

Authors:  Chen-Tian Shen; Zhong-Ling Qiu; Hong-Jun Song; Wei-Jun Wei; Quan-Yong Luo
Journal:  J Exp Clin Cancer Res       Date:  2016-06-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.